Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics (Nasdaq: MCRB) announced two publications in Nature Medicine and the Journal of Infectious Diseases detailing VOWST™ functional mechanism and clinical translation.
The Nature Medicine paper reported dose-related faster engraftment, shifts in gut metabolites (decreased primary/increased secondary bile acids; higher short- and medium-chain fatty acids) that inhibit C. difficile germination and growth. The Journal of Infectious Diseases analysis found similar gastrointestinal microbiome and bile acid profiles in first and multiply recurrent C. difficile patients, with comparable VOWST pharmacology and efficacy across groups.
Seres noted these MbTx platform data supported its pipeline, including lead candidate SER-155, whose randomized Phase 1b showed a 77% reduction in bacterial bloodstream infections and reduced antibiotic use in allo-HSCT patients.
Seres Therapeutics (Nasdaq: MCRB) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:30 a.m. ET. A live webcast will be accessible via the company’s Investors and News "Events and Presentations" page and will be available for replay after the event.
The presentation offers investors a real-time update opportunity and a post-event replay for later review.
Seres Therapeutics (Nasdaq: MCRB) reported Q3 2025 results and business updates on November 5, 2025.
Key points: $47.6M cash as of September 30, 2025; company expects to fund operations through Q2 2026. Seres is finalizing the SER-155 Phase 2 protocol for prevention of bloodstream infections in allo-HSCT, planning ~248 participants with an adaptive design and an interim analysis when ~half reach the primary endpoint; interim results are anticipated within 12 months of study start pending funding. Seres received a CARB-X grant up to $3.6M, presented new SER-155 Phase 1b post-hoc data at IDWeek 2025, and continues an investigator-sponsored trial in irEC with initial readout expected in early 2026.
Q3 operating highlights include R&D $12.6M, G&A $9.5M, and net income from continuing operations of $8.2M driven by a $27.2M gain on sale of VOWST.
Seres Therapeutics (Nasdaq: MCRB) will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and business updates.
Dial-in numbers are 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 8471287. The live webcast is available via the Investors and News section at www.serestherapeutics.com. A replay will be posted shortly after the event and archived for approximately 21 days.
Seres Therapeutics (Nasdaq: MCRB) received up to $3.6 million in non-dilutive funding from CARB-X to develop and manufacture an oral liquid formulation of SER-155 for medically vulnerable patients who cannot take capsules, including intubated ICU patients.
SER-155, developed for allo-HSCT patients, showed a 77% reduction in bacterial bloodstream infections (BSIs) versus placebo in a randomized Phase 1b study and reduced systemic antibiotic use and febrile neutropenia. The company received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the clinical protocol.
Seres Therapeutics (Nasdaq: MCRB) announced new post hoc data from the SER-155 Phase 1b trial will be presented orally at IDWeek 2025 on October 20, 2025. The presentation reports differences between SER-155 and placebo in bacterial and fungal bloodstream infection (BSI) pathogens, clinical BSI outcomes, antibacterial prophylaxis use, and antimicrobial resistance patterns.
Key disclosed result: in the randomized, double-blind Phase 1b cohort, SER-155 reduced BSIs by 77% and lowered systemic antibiotic use and febrile neutropenia. The company said it received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the protocol while pursuing capital to advance SER-155 and its live biotherapeutics portfolio.
Seres Therapeutics (NASDAQ:MCRB) has received constructive FDA feedback on its Phase 2 study protocol for SER-155, a breakthrough therapy-designated treatment for preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant.
The planned Phase 2 study will be placebo-controlled with 248 participants, focusing on preventing bloodstream infections through 30 days post-transplant. An interim analysis is expected within 12 months of study initiation.
To extend its cash runway into Q2 2026, Seres is implementing cost reduction measures, including a 25% workforce reduction with severance costs of $1.0-$1.4 million. The company continues seeking capital to advance the SER-155 study and its broader portfolio.
Seres Therapeutics (Nasdaq: MCRB), a live biotherapeutics company, will participate in the H.C. Wainwright Global Investment Conference in New York City. The company's management will deliver a corporate presentation on September 8, 2025 at 3:00 p.m. ET.
A webcast replay of the presentation will be accessible on the Seres website approximately two hours after the event and will remain available for 21 days.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 2025 financial results and business updates. The company submitted a Phase 2 study protocol to FDA for SER-155, targeting bloodstream infection prevention in stem cell transplant patients. The planned study will enroll 248 participants with interim analysis expected within 12 months of initiation.
Key financial highlights include a net loss of $19.9 million in Q2 2025, reduced from $26.2 million in Q2 2024. The company received a $25 million payment from Nestlé Health Science in July 2025 and expects to fund operations into Q1 2026. Management changes include the appointment of Thomas DesRosier and Marella Thorell as co-CEOs, effective August 1, 2025.
Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
